Tag Archives: Anni

Celgene Corp to pay 280M to settle cancer drug fraud suit

LOS ANGELES, Calif. – Celgene Corp. has agreed to pay $280 million to settle a whistleblower lawsuit alleging the pharmaceutical company committed fraud promoting a drug with a notorious history that was re-purposed to treat leprosy and another therapy for unapproved cancer treatments, federal prosecutors announced Tuesday.The agreement settled a lawsuit in Los Angeles federal court by a former Celgene saleswoman who said the New Jersey-based company submitted false claims to Medicare and health care programs in 28 states and Washington, D.C., which were all parties to the settlement.“Patients deserve to know their doctors are prescribing drugs that are likely to provide effective treatment, rather than drugs marketed aggressively by pharmaceutical companies,” said Acting U.S. Attorney Sandra R. Brown.The lawsuit filed by Beverly Brown was brought on behalf of the U.S. government under a federal whistleblower law. She could receive as much as $84 million as her share of the settlement.Celgene denied wrongdoing and settled to avoid uncertainty, distraction and expensive litigation, the company said in a statement.Brown was an “immunology specialist” trained by Celgene to promote Thalomid and Revlimid drugs for cancer treatments that had not been approved by the U.S. Food and Drug Administration, the lawsuit said.Thalomid, another name for thalidomide, a drug prescribed for morning sickness in the 1950s and 1960s that caused severe birth defects, was approved by the agency in 1998 for treating leprosy.Because Thalomid would only be useful to a fraction of the few hundred leprosy cases diagnosed in the U.S. each year, the company developed a plan to promote the drug for cancer, the lawsuit said.Doctors can prescribe drugs for other purposes if they think they will be effective, and the company marketed the drug directly to them to treat blood cancers and tumors, the lawsuit said.The FDA contacted Celgene and sent letters warning about its promotional efforts and for failing to warn about potential fatal risks from the toxic drugs, the lawsuit said.“Their use in off-label indications was tantamount to human experimentation,” Brown’s lawyers wrote in one court filing. “Celgene compounded this by instructing its sales representatives to conceal the drugs’ risks, including most notably the potential for lethal blood clots.”While Thalomid and Revlimid, a successor derived from thalidomide, were later approved for limited cancer treatments, their widespread promotion in advance of approvals led Celgene “from the verge of extinction to the multi-billion company it is today,” the lawsuit said.In one of its annual reports, the company said in 1999 that 90 per cent of Thalomid prescriptions were for cancer and the drug earned more than $100 million a year in sales through 2005, when it earned approximately $389 million, the lawsuit said. Revlimid brought in more than $1.7 billion in 2008 and 2009, the lawsuit said.The lawsuit also claimed Celgene used false and misleading statements and paid kickbacks to doctors to prescribe the drugs.A judge threw out the kickbacks allegation last year, but allowed the lawsuit to proceed.Under the False Claims Act, Brown can receive 25 per cent to 30 per cent of the settlement. She would have been eligible for a smaller share if the government had intervened to take over the case.In 2012, a former banker earned $104 million — the largest individual government whistleblower award — for helping expose a widespread tax evasion scheme by the Swiss banking behemoth UBS AG.For Brown, who brought the case in 2010 after leaving the company, it was a long and, at times, emotional experience, attorney Thomas Bienert said.“I’m extremely pleased to have been a part of recouping this amount of money for the taxpayer and for seeing our courageous client, Beverly Brown, vindicated in pursuing this matter,” Bienert said. Celgene Corp. to pay $280M to settle cancer drug fraud suit by Brian Melley, The Associated Press Posted Jul 25, 2017 3:02 pm MDT Last Updated Jul 25, 2017 at 9:20 pm MDT AddThis Sharing ButtonsShare to TwitterTwitterShare to FacebookFacebookShare to RedditRedditShare to 電子郵件Email read more

Motor show news update – 29 May

Lotto winners spoilt for choice at Motor Show Live Families see show as a holiday highlight Bentley lays on VIP trips to show from Cheltenham, Leeds & Rochdale Lotto winners spoilt for choice at Motor Show Live If the car of their dreams is the first luxury purchase of many lottery winners, then the winner of tonight’s estimated £21.5 million triple roll-over jackpot would be spoilt for choice at The Sunday Times Motor Show Live.In fact, they would be able to buy all of the 400 cars on display and still have £6.5 million left in loose change!Taking the biggest dent out of the winner’s newly inflated bank balance would be the £313,465 Mercedes SLR McLaren, closely followed by the £300,000 Porsche Carrera GT and the £281,380 Maybach. Also likely to figure prominently in any list of dream cars are the £214,500 Rolls-Royce Phantom, the £177,500 Ferrari 612 Scaglietti and the £112,000 Aston Martin DB9 Volante. Families see show as a holiday highlight A whole new family audience is making a Bank Holiday B-line for The Sunday Times Motor Show Live, attracted by new interactive features that make the show a great day out.This year’s event is a radical departure from previous shows, with the emphasis as much on all-round family entertainment as the 400 new cars that are on display.Already proving a star attraction at the show is the BSM Driving School, at which children as young as 14 can actually drive a car for the first time. Younger family members will delight at the Lego-built Fomula 1 car and play area on the Fiat stand in Hall 5.The whole family, meanwhile, will enjoy the thrills and spills of the 4×4 Experience, a specially built off-road course, before getting a pure adrenalin fix at the Motropolis Live Action Arena, the MINI Open Air Theatre and Comma Caterham Experience.The show’s PR director, Andrew Andersz, says: ‘The show is no longer simply the preserve of car enthusiasts and petrolheads, it’s now an interactive experience that’s a must-visit event for the family over the Bank Holiday weekend and throughout the School holidays. Bentley lays on VIP trips to show from Cheltenham, Leeds & Rochdale Three competition winners and their partners are travelling to The Sunday Times Motor Show Live in the lap of luxury this weekend – chauffeur driven to and from the show in a Bentley Arnage.The winners are being given the VIP treatment after taking part in a poll of Auto Express readers, which revealed that Britain’s best loved car of the last 50 years is the Jaguar E-Type. The three winners are: Graham Owen from Cheltenham, Ben Fox from Leeds and Iain Brown from Rochdale.They all voted for the Jaguar E-type in the poll, paying homage to a model favoured by racing legends Jackie Stewart and Graham Hill. Visitors to Motor Show Live can catch a glimpse of the E-type, as it makes a cameo appearance in the Motropolis Live Action Arena.Graham Owen, who was accompanied by his wife Dawn on their visit to the show, said: ‘We’ve had a fantastic day. We really enjoyed seeing all the extra features including the Metropolis Live Action Arena and Thunderbirds. This was only bettered by being treated like royalty for the day thanks to Auto Express!’Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window) read more